Recent Updates
Recently added Catalysts

AN2718

Phase 1

Tinea Pedis | Small molecule | Other |Pfizer, Inc.|Last Updated: Apr 16, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment44
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00781664Cumulative Irritation TestPHASE1 COMPLETED 44Oct 1, 2008Nov 1, 2008Apr 16, 20191 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Irritation Score (5-point scale)
Daily for 21 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeOTHER
Treatment Arms
ArmTypeDescription
AEXPERIMENTALAN2718 Cream SF Vehicle
BEXPERIMENTALAN2718 Cream SF, 0.3%
CEXPERIMENTALAN2718 Cream SF, 1%
DEXPERIMENTALAN2718 Gel Vehicle
EEXPERIMENTALAN2718 Gel, 1.5%
FEXPERIMENTALAN2718 Gel, 2.5%
GEXPERIMENTALAN2718 Gel, 5%
HEXPERIMENTALAN2718 Gel, 7.5%
IACTIVE_COMPARATORSodium Lauryl Sulfate, 0.5%
Interventions
NameTypeDescription
AN2718OTHERAN2718 Cream SF Vehicle, Daily for up to 21 days
Sodium Lauryl SulfateOTHERSodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: Subjects must meet all of the following criteria for inclusion in the study. 1. Healthy volunteers of either sex, at least 18 years of age or older. 2. Females must be of non-childbearing potential (i.e., post-menopausal or surgically sterile \[bilateral oophorectomy and/or tot...

Countries:United States
Unlock Eligibility Criteria